Table 2. Reported Side-effects During peG-IFn-α Therapy.
Intravenous Drug Users, No. (%) (n = 106) | No History of Drug Abuse, No. (%)(n = 239) | |
Anemia | 19 (17.92) | 45 (18.82) |
Neutropenia | 7 (6.66) | 26 (10.87) |
Thrombocytopenia | 5 (4.71) | 19 (7.94) |
Atralgiae/mialgiae | 8 (7.54) | 21 (8.78) |
Dermatological (including dermatitis, rash, pruritus) | 26 (24.52) | 68 (28.45) |
Hipo/hiperthyreosis | 3 (2.83) | 6 (2.51) |
Flu-like symptoms | 49 (46.23) | 108 (45.18) |
Respiratory symptoms | 2 (1.88) | 3 (1.25) |
Anxiety | 21 (19.81) | 35 (14.64) |
Depression | 9 (8.49) | 6 (2.51) |
Insomnia | 8 (7.54) | 6 (2.51) |
Headache | 36 (33.96) | 78 (32.63) |